Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
待确认10由 Aixuexi 发布于 2026/7/29 17:46:27
DOI:10.1016/S0140-6736(19)32591-7
作者:B. Burtness,?K. Harrington,?R. Greil,?D. Soulières,?M. Tahara,?G. D. Castro,?A. Psyrri,?N. Basté,?P. Neupane,?A. Bratland,?T. Fuereder,?B. Hughes,?R. Mesía,?N. Ngamphaiboon,?T. Rordorf,?W. Z. W. Is
文献类型:期刊论文
补充材料:只需要正文